Literatur
-
1
Anderson G L, Limacher M, Assaf A R. et al. Women’s Health Initiative Steering Committee .
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial.
JAMA.
2004;
291
1701-1712
-
2
Beral V. Million Women Study Collaborators .
Breast cancer and hormone-replacement therapy in the Million Women Study.
Lancet.
2003;
362
419-427
-
3
Brass L M.
Hormone replacement therapy and stroke: clinical trials review.
Stroke.
2004;
35
2644-2647
-
4
Cauley J A, Lucas F L, Kuller L H, Vogt M T, Browner W S, Cummings S R. Study of Osteoporotic Fractures Research Group .
Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures.
JAMA.
1996;
276
1404-1408
-
5
Cauley J A, Robbins J, Chen Z. et al. Women’s Health Initiative Investigators .
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial.
JAMA.
2003;
290
1729-1738
-
6
Cherry N, Gilmour K, Hannaford P. et al. ESPRIT team .
Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial.
Lancet.
2002;
360
2001-2008
-
7
Chlebowski R T, Hendrix S L, Langer R D. et al .
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial.
JAMA.
2003;
289
3243-3253
-
8
Col N F, Weber G, Stiggelbout A, Chuo J, D’Agostino R, Corso P.
Short-term menopausal hormone therapy for symptom relief: an updated decision model.
Arch Intern Med.
2004;
164
1634-1640
-
9
Collaborative Group on Hormonal Factors in Breast Cancer .
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer.
Lancet.
1997;
350
1047-1059
-
10
Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F.
Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort.
Int J Cancer.
2004;
online publication
-
11
Gambacciani M.
New HRT Options for the Treatment of Menopausal Symptoms and the Maintenance of Quality of Life in Postmenopausal Women.
Endocrine.
2004;
24
231-238
-
12
Grady D, Rubin S M, Petitti D B, Fox C S, Black D, Ettinger B, Ernster V L, Cummings S R.
Hormone therapy to prevent disease and prolong life in postmenopausal women.
Ann Intern Med.
1992;
117
1016-1037
-
13
Grodstein F, Manson J E, Colditz G A, Willett W C, Speizer F E, Stampfer M J.
A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.
Ann Intern Med.
2000;
133
933-941
-
14
Haas J S, Kaplan C P, Gerstenberger E P, Kerlikowske K.
Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results.
Ann Intern Med.
2004;
140
184-188
-
15
Hays J, Ockene J K, Brunner R L, Kotchen J M. et al. Women’s Health Initiative Investigators .
Effects of estrogen plus progestin on health-related quality of life.
N Engl J Med.
2003;
348
1839-1854
-
16
Henderson B E, Paganini-Hill A, Ross R K.
Decreased mortality in users of estrogen replacement therapy.
Arch Intern Med.
1991;
151
75-78
-
17
Hodis H N, Mack W J, Lobo R A. et al. Estrogen in the Prevention of Atherosclerosis Trial Research Group .
Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med.
2001;
135
939-953
-
18
Hofseth L J, Raafat A M, Osuch J R, Pathak D R, Slomski C A, Haslam S Z.
Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast.
J Clin Endocrinol Metab.
1999;
84
4559-4565
-
19
Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Heart and Estrogen/progestin Replacement Study (HERS) Research Group .
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.
JAMA.
1998;
280
605-613
-
20
Humphrey L L, Chan B K, Sox H C.
Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease.
Ann Intern Med.
2002;
137
273-284
-
21
Lahmann P H, Hoffmann K, Allen N. et al .
Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC).
Int J Cancer.
2004;
111
762-771
-
22
Löwel H, Heier M, Schneider A, Gösele U, Meisinger C.
Hormontherapie (II): Vergleiche sind zulässig.
Deutsches Ärzteblatt.
2003;
100
A2561-2562
-
23
Manson J E, Hsia J, Johnson K C. et al. Women’s Health Initiative Investigators .
Estrogen plus progestin and the risk of coronary heart disease.
N Engl J Med.
2003;
349
523-534
-
24
Matthews K A, Kuller L H, Wing R R, Meilahn E N, Plantinga P
.
Prior to use of estrogen replacement therapy, are users healthier than nonusers?.
Am J Epidemiol.
1996;
143
971-978
-
25
Mendelsohn M E, Karas R H.
The protective effects of estrogen on the cardiovascular system.
N Engl J Med.
1999;
340
1801-1811
-
26
Miller J, Chan B K, Nelson H D.
Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force.
Ann Intern Med.
2002;
136
680-690
-
27
Psaty B M, Heckbert S R, Atkins D. et al .
The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women.
Arch Intern Med.
1994;
154
1333-1339
-
28 Pressemitteilung des BfARM vom 06.05.2004:. http://bfarm.de
-
29
Rossouw J E, Anderson G L, Prentice R L. et al. Women’s Health Initiative Investigators .
Writing Group for the Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.
JAMA.
2002;
288
321-333
-
30
Scarabin P Y, Oger E, Plu-Bureau G.
EStrogen and THromboEmbolism Risk Study Group Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.
Lancet.
2003;
362
428-432
-
31
Wassertheil-Smoller S, Hendrix S L, Limacher. et al .
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial.
JAMA.
2003;
289
2673-2684
-
32
Writing group for the PEPI Trial .
Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA.
1995;
273
199-208
-
33
Zhang Y, Kiel D P, Kreger B E. et al .
Bone mass and the risk of breast cancer among postmenopausal women.
N Engl J Med.
1997;
336
611-617
Prof. Dr. med. H. Lehnert
Klinik für Endokrinologie und Stoffwechselkrankheiten, Otto-von-Guericke-Universität Magdeburg
Leipziger Straße 44
39120 Magdeburg
Phone: 0391/6715445
Fax: 0391/6715489
Email: hendrik.lehnert@medizin.uni-magdeburg.de
